COVID-19 in 2021

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2021 Oct 26

PMID 34696528

Citations 2

Authors

Kenneth Lundstrom

Alaa A A Aljabali

Affiliations

Soon will be listed here.

Abstract

The Special Issue on Vaccines and Therapeutics against Coronaviruses, which was launched in early 2021, has attracted the scientific community at large, and more than 20 manuscripts have been accepted for publication.[...].

Citing Articles

COVID-19 signalome: Potential therapeutic interventions.

Lundstrom K, Hromic-Jahjefendic A, Bilajac E, Aljabali A, Baralic K, Sabri N Cell Signal. 2022; 103:110559.

PMID: 36521656 PMC: 9744501. DOI: 10.1016/j.cellsig.2022.110559.

[The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies].

Monschein T, Zrzavy T, Lobermann M, Winkelmann A, Berger T, Rommer P Nervenarzt. 2021; 92(12):1283-1292.

PMID: 34232358 PMC: 8261806. DOI: 10.1007/s00115-021-01154-5.

References

Lennerstrand J, Palanisamy N . Global Prevalence of Adaptive and Prolonged Infections' Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. Viruses. 2021; 13(10). PMC: 8538289. DOI: 10.3390/v13101974. View

Ivashchenko A, Azarova V, Egorova A, Karapetian R, Kravchenko D, Krivonos N . Effect of Aprotinin and Avifavir Combination Therapy for Moderate COVID-19 Patients. Viruses. 2021; 13(7). PMC: 8310315. DOI: 10.3390/v13071253. View

Akhter J, Queromes G, Pillai K, Kepenekian V, Badar S, Mekkawy A . The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. Viruses. 2021; 13(3). PMC: 7999995. DOI: 10.3390/v13030425. View

Funk C, Laferriere C, Ardakani A . Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. Viruses. 2021; 13(3). PMC: 7998902. DOI: 10.3390/v13030418. View

Xia X . Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design. Viruses. 2021; 13(1). PMC: 7829931. DOI: 10.3390/v13010109. View

Morita T, Miyakawa K, Jeremiah S, Yamaoka Y, Sada M, Kuniyoshi T . All-Trans Retinoic Acid Exhibits Antiviral Effect against SARS-CoV-2 by Inhibiting 3CLpro Activity. Viruses. 2021; 13(8). PMC: 8402917. DOI: 10.3390/v13081669. View

Ben-Zuk N, Dechtman I, Henn I, Weiss L, Afriat A, Krasner E . Potential Prophylactic Treatments for COVID-19. Viruses. 2021; 13(7). PMC: 8310088. DOI: 10.3390/v13071292. View

Bormann M, Alt M, Schipper L, van de Sand L, Le-Trilling V, Rink L . Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro. Viruses. 2021; 13(10). PMC: 8537626. DOI: 10.3390/v13101914. View

Reardon S . Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature. 2021; 596(7871):173-174. DOI: 10.1038/d41586-021-02081-w. View

10.

Tumban E . Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses. 2021; 13(1). PMC: 7824305. DOI: 10.3390/v13010054. View

11.

Andrade B, Siqueira S, de Assis Soares W, de Souza Rangel F, Santos N, Dos Santos Freitas A . Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses. 2021; 13(4). PMC: 8072585. DOI: 10.3390/v13040700. View

12.

van de Sand L, Bormann M, Alt M, Schipper L, Silke Heilingloh C, Steinmann E . Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease. Viruses. 2021; 13(4). PMC: 8066091. DOI: 10.3390/v13040609. View

13.

Bharadwaj S, Aly El-Kafrawy S, Alandijany T, Bajrai L, Shah A, Dubey A . Structure-Based Identification of Natural Products as SARS-CoV-2 M Antagonist from Using Computational Approaches. Viruses. 2021; 13(2). PMC: 7919488. DOI: 10.3390/v13020305. View

14.

Fricke-Galindo I, Falfan-Valencia R . Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. Viruses. 2021; 13(3). PMC: 7998786. DOI: 10.3390/v13030413. View

15.

Ko M, Chang S, Byun S, Ianevski A, Choi I, DOrengiani A . Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19. Viruses. 2021; 13(4). PMC: 8069929. DOI: 10.3390/v13040651. View

16.

Bae S, Ghang B, Kim Y, Lim J, Yun S, Kim Y . Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. Viruses. 2021; 13(2). PMC: 7924588. DOI: 10.3390/v13020329. View

17.

Lundstrom K . RNA Viruses as Tools in Gene Therapy and Vaccine Development. Genes (Basel). 2019; 10(3). PMC: 6471356. DOI: 10.3390/genes10030189. View

18.

Fink K, Nitsche A, Neumann M, Grossegesse M, Eisele K, Danysz W . Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses. 2021; 13(4). PMC: 8063946. DOI: 10.3390/v13040539. View

19.

Chong W, Chellappan D, Shukla S, Peterson G, Patel R, Jha N . An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Viruses. 2021; 13(7). PMC: 8310376. DOI: 10.3390/v13071397. View

20.

Peiffer-Smadja N, Bridier-Nahmias A, Ferre V, Charpentier C, Gare M, Rioux C . Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021; 13(8). PMC: 8402761. DOI: 10.3390/v13081642. View